Children exposed to chemotherapy or radiotherapy in utero suffer no negative impacts on mental or cardiac development, according to international studies presented at ESMO 2014. These findings confirm that chemotherapy and radiotherapy during pregnancy do not endanger the fetus and its subsequent development.
The phase III trials indicate that anamorelin is safe and well-tolerated in treating symptoms of advanced non-small cell lung cancer anorexia-cachexia. Patients experienced improvements in lean body mass, body weight, and patient symptoms/concerns regarding appetite over 12 weeks.
Biennial colorectal cancer screening in France's Cote-D'Or region increased the rate of diagnosis of high-risk pre-cancerous adenomas by 89%. The study also found that fecal occult blood testing may be more efficient than colonoscopy for high-risk patients.
A phase III trial demonstrated that afatinib significantly improved progression-free survival compared to methotrexate in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. The study showed a 20% reduction in risk of progression or death, with patients experiencing less pain over time.
A direct comparison of docetaxel and pemetrexed with cisplatin shows similar progression-free survival rates, but docetaxel is associated with more frequent adverse events. The study included 149 patients with non-squamous lung cancer and found that the pemetrexed combination was less toxic.
A new study published in Science Express reviews progress in addressing challenges using evolutionary histories and rapid adaptation approaches. The research highlights the urgent need for better implementation of these strategies to combat escalating resistance to antibiotics and pesticides.
A Korean study showed that patients with low levels of thymidylate synthase in their lung tumors experienced greater benefits from treatment with pemetrexed and cisplatin. The enzyme's expression level can also serve as a prognostic biomarker for overall survival.
A phase III trial showed that Rolapitant significantly reduced nausea and vomiting in patients receiving cisplatin-based chemotherapy. The study found that 72.7% of patients experienced complete response, with improved quality of life outcomes.
Researchers report that crizotinib effectively halted tumor growth in 36 of 50 study participants and suppressed it in another 9. The study confirmed that ROS1 is a viable therapeutic target for ROS1-positive lung cancer patients.